Daewoong Pharma (069620) stock
KOSPI · Pharmaceuticals
As of Nov 16, 1:05 PM KST
Events and reference metrics · 1
- Market cap
- KRW 1.2 trillion
- As of Nov 16, 2026
- P/E
- 6.40x
- Trailing twelve months
- P/B
- 1.14x
- Latest reported equity
- P/S
- 0.70x
- Trailing twelve months
- ROE
- 17.9%
- Trailing twelve months
- Dividend yield
- 0.59%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 1.2 trillion
- As of Nov 16, 2026
- P/E
- 6.40x
- Trailing twelve months
- P/B
- 1.14x
- Latest reported equity
- P/S
- 0.70x
- Trailing twelve months
- ROE
- 17.9%
- Trailing twelve months
- Dividend yield
- 0.59%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
6.40x
P/B
1.14x
P/S
0.70x
Earnings and dividend metrics▾
Earnings
EPS
KRW 15,840
Earnings per share
BPS
KRW 88,551
Book value per share
ROE
17.9%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 15,840 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 88,551 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 17.9%.
Dividends
1 observed in the last year · Record dates: Dec
Yield
0.59%
Dividend per share
KRW 600
Payout ratio
3.5%
Consecutive years
4+ yrs
Yield uses dividends observed over the last year (by record date) · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about KRW 60,000 before tax.
- Payout ratio — 3.5% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 4 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 448.5 billion | KRW 68.1 billion | KRW 19.9 billion | +10.6% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 377.8 billion | KRW 22.2 billion | KRW 25.5 billion | +6.0% |
| Q4 2025Consolidated · Filed Mar 18, 2026 | KRW 397.1 billion | KRW 43.3 billion | KRW 85.7 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 411.8 billion | KRW 56.9 billion | KRW 47.3 billion | +14.9% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 405.4 billion | KRW 57.9 billion | KRW 40.1 billion | +12.5% |
| Q1 2025Consolidated · Filed May 15, 2025 | KRW 356.5 billion | KRW 38.7 billion | KRW 19.8 billion | +6.2% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 18, 2026 | KRW 1.6 trillion | KRW 196.8 billion | KRW 192.9 billion | — |
| FY2024Consolidated · Filed Aug 14, 2025 | KRW 1.4 trillion | KRW 147.9 billion | KRW 23.3 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 14.67%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 300 million
- Previous 20-day average 16.01%
- Net short position
- 39,955 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 349,971 shares
- As of Nov 13, 2026 · 3.02% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 14.67% | KRW 300 million |
| Nov 12, 2026 | 18.07% | KRW 600 million |
| Nov 11, 2026 | 15.77% | KRW 260 million |
| Nov 10, 2026 | 8.95% | KRW 150 million |
| Nov 9, 2026 | 7.10% | KRW 160 million |
| Nov 6, 2026 | 8.90% | KRW 220 million |
| Nov 5, 2026 | 14.37% | KRW 460 million |
| Nov 4, 2026 | 27.49% | KRW 560 million |
| Nov 3, 2026 | 21.17% | KRW 440 million |
| Nov 2, 2026 | 16.59% | KRW 230 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Preliminary Operating Results (Fair Disclosure)Nov 4, 2026 · Preliminary EarningsEnglish
- Advance Notice of Designation as Unfaithful Disclosure Corporation(Korean)Nov 2, 2026 · Key Risk Notice
- Termination of Single Sales or Supply ContractNov 2, 2026 · Supply ContractEnglish
- Results of Extraordinary General Meeting(Korean)Sep 9, 2026 · Shareholders Meeting
- Decision on Debt Guarantee for Others(Korean)Sep 4, 2026 · Debt Guarantee or Loan
- Filing of Lawsuit or Petition (Claim Above Threshold)(Korean)Sep 2, 2026 · Key Risk Notice
- Proxy Solicitation Reference Document(Korean)Aug 25, 2026 · Proxy Solicitation
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Aug 21, 2026 · Insider Ownership Report
Filings with a published English version open in English; the rest link to the Korean original.
Daewoong Pharma (069620) stock information
KOSPI
Daewoong Pharma (069620) is listed on KOSPI. Its market capitalization is about KRW 1.2 trillion. On trailing-twelve-month earnings the P/E ratio is 6.4, and the P/B ratio is 1.14. Return on equity is 17.9%. These figures are computed in-house from official filings and are reference information only.
Daewoong Pharma — frequently asked questions
- What is the P/E ratio of Daewoong Pharma (069620)?
- On a trailing-twelve-month basis, 069620 trades at a P/E ratio of 6.4. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Daewoong Pharma?
- 069620 has a market capitalization of about KRW 1.2 trillion. The figure moves with the share price and is refreshed each trading day.
- Does Daewoong Pharma pay a dividend?
- 069620 has a dividend yield of about 0.59%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.